Bispecific Antibody Market: By Type (IgG Like Molecule, Non-IgG Like Molecule), By Application (Oncology, Autoimmune Disease and Others), By Geography

Purchase Option

$ 3000
$ 4400
$ 6600
$ 8900

The global Bispecific Antibody Market size was valued at USD x billion in 2021, growing at a CAGR of x% during the forecast period 2022-2028. Gowing to launch of new products in the market in the future years. For instance, there are more than 200 bispecific antibodies products in the clinical trials which will be launched mostly among them in the future years. Increasing investments in research and development of the development of bispecific antibody market products and rising prevalence of cancer. According to WHO, around 9.6 people across the globe are responsible for death due to cancer. Presently only two drugs are approved by the U.S.FDA catumaxomab and blinatumomab. Around 30 bispecific antibodies are expected to be launched in the upcoming years that increases the growth of the market. However, limited number of products available in the market and lack of awareness among the patient population restrains the growth of the market. A bispecific antibody is a synthetic protein made up of fragments from two distinct monoclonal antibodies that can bind to two different types of antigens. The most well-studied application of bispecific antibodies is cancer immunotherapy. The majority of bispecific antibodies are being created to treat various malignancies, with infectious disease, CNS diseases, inflammatory, and autoimmune disorders following closely behind. Bispecific antibodies have a higher binding avidity to targets, can interact with more than one surface antigen, and have more cytotoxic effects than monoclonal therapies.

Bispecific Antibody Market Summary

Study Period


Base Year




Largest Market


Fastest Growing Market


A number of pharmaceutical companies are actively involved in research and development of the bispecific antibodies. To launch the products to strengthen their position in the market and expand their product portfolio to offer better services to their patients. Manufacturers are also following various strategies to speed the development process for immediate launch of the products as soon as possible. For instance, In Dec 2016, MedImmune, LLC and Abpro, collaborated to develop novel bispecific antibody, Ang2-VEGF, which targets angiopoietin-2 and vascular endothelial growth factor.

Key Features of the Reports

  • Global bispecific antibody market expanding at significant CAGR over 2021 to 2027 owing to number of bispecific antibodies in clinical trials and increasing investments by the market players.
  • Based on region, North America accounted for larger market revenue share in 2020 and projected gain market revenue share over the forecast period
  • Players focusing on innovation of newer products and collaboration strategies to retain market position in global market

Bispecific Antibody Market Segmentation

By Type
  • IgG Like Molecule
  • Non-IgG Like Molecule
By Application
By Geography
North America
  • US
  • Canada
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Russia
  • Poland
  • Rest of Europe
  • Japan
  • China
  • India
  • Australia & New Zealand
  • ASEAN (Includes Indonesia, Thailand, Vietnam, Philippines, Malaysia, and Others)
  • South Korea
  • Rest of Asia-Pacific
Latin America
  • Brazil
  • Mexico
  • Argentina
  • Venezuela
  • Rest of Latin America
Middle East and Africa (MEA)
  • Gulf Cooperation Council (GCC) Countries
  • Israel
  • South Africa
  • Rest of MEA

Frequently Asked Questions

2021 is the base year and 2028 is the forecast year.

The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).

In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.

  • Ablynx
  • Adimab
  • Affimed Therapeutics
  • Amgen
  • AstraZeneca (MedImmune)
  • Chugai Pharmaceutical
  • Eli Lilly
  • EMD Serono
  • Emergent BioSolutions
  • Genentech
  • Genmab
  • Immunomedics
  • Jounce Therapeutics
  • MacroGenics
  • Merus
  • Neovii Biotech
  • NovImmune
  • OncoMed Pharmaceuticals
  • Pieris
  • Regeneron Pharmaceuticals
  • Roche
  • Sanofi